Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib

Background: Sorafenib was the first systemic therapy approved for the treatment of Child-Turcotte-Pugh (CTP) class A patients with advanced hepatocellular carcinoma (HCC). However, there are no biomarkers to predict survival and treatment outcomes and guide HCC systemic therapy. Type 1 insulin-like...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Yehia I., Lee, Sunyoung, Xiao, Lianchun, Hassan, Manal M., Qayyum, Aliya, Hiatia, Rikita, Pestana, Roberto Carmagnani, Haque, Abedul, George, Bhawana, Rashid, Asif, Duda, Dan G., Elghazaly, Hesham, Wolff, Robert A., Morris, Jeffrey S., Yao, James, Amin, Hesham M., Kaseb, Ahmed O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057275/
https://www.ncbi.nlm.nih.gov/pubmed/33889299
http://dx.doi.org/10.18632/oncotarget.27924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057275/
https://www.ncbi.nlm.nih.gov/pubmed/33889299
http://dx.doi.org/10.18632/oncotarget.27924

Ejemplares similares